Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

>AVEOwhether they would rather focus on other indications

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
biomaven0 Member Profile
Member Level 
Followed By 62
Posts 3,777
Boards Moderated 0
Alias Born 02/27/07
160x600 placeholder
U.S. Stocks: Futures Higher At The Start Of Holiday-shortened Week
U.S. stock futures advanced Monday at the beginning of a holiday-shortened week, suggesting Wall Street is ready to build on its multi-week run of gains.
Top Equities Stories Of The Day
BHP Billiton PLC BHP Billiton 2014 Demerger Update
Taiwan Output Hits New High, but Government Warns of Slowdown
Intel Projects More Growth in 2015 -- Update
Faith-Based Shareholders Prepare Day of Reckoning for Bank of America
Wireless Carriers Bid Up US Airwaves To Record
Bangladesh Police Say Extremists Didn't Kill Professor
BBVA Raises $2.5 Billion for Garanti Stake Purchase
Alibaba Becomes Wall Street's Favorite Customer -- 3rd Update
biomaven0 Member Level  Thursday, 09/08/11 09:41:43 AM
Re: NP1986 post# 126293
Post # of 184136 
>AVEO

Quote:
whether they would rather focus on other indications



My guess is they will try to go for combination therapy - any place where Avastin has shown good results in combination would be a good place to start.

In terms of going up against Sutent vs. against Nexavar, it's somewhat instructive that Pfizer made the same choice in 2nd line for their drug. I'm of the view that a small company should almost always take the easiest path to registration - worry about expanding the market once you have approval.

Peter

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist